Tags

Type your tag names separated by a space and hit enter

Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. I. Single-dose study.
Am Rev Respir Dis 1988; 138(4):882-5AR

Abstract

A comparative bioavailability study of the antituberculosis drugs isoniazid, rifampin, and pyrazinamide was carried out in a group of 10 healthy volunteers after administration of the three compounds, once in individual association and once in a combined, fixed preparation. The investigation was designed as an open, crossover study where each subject received five tablets of a preparation containing 50 mg isoniazid, 120 mg rifampin, and 300 mg pyrazinamide (corresponding to a total dose of 250 mg isoniazid, 600 mg rifampin, and 1,500 mg pyrazinamide). The same doses were administered in the session where the drugs were combined using the individual formulations. For each subject and experimental session, 15 blood samples were collected over a period of 24 h, and the plasma concentrations of the three drugs were assessed. The results indicated the absence of negative pharmacokinetic interactions between the drugs when administered in both free and this new, fixed combination.

Authors+Show Affiliations

Reference Center for Chemotherapy of Mycobacterial Diseases, Istituto Forlanini, Pavia, Italy.

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

3202464

Citation

Acocella, G, et al. "Comparative Bioavailability of Isoniazid, Rifampin, and Pyrazinamide Administered in Free Combination and in a Fixed Triple Formulation Designed for Daily Use in Antituberculosis Chemotherapy. I. Single-dose Study." The American Review of Respiratory Disease, vol. 138, no. 4, 1988, pp. 882-5.
Acocella G, Nonis A, Gialdroni-Grassi G, et al. Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. I. Single-dose study. Am Rev Respir Dis. 1988;138(4):882-5.
Acocella, G., Nonis, A., Gialdroni-Grassi, G., & Grassi, C. (1988). Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. I. Single-dose study. The American Review of Respiratory Disease, 138(4), pp. 882-5.
Acocella G, et al. Comparative Bioavailability of Isoniazid, Rifampin, and Pyrazinamide Administered in Free Combination and in a Fixed Triple Formulation Designed for Daily Use in Antituberculosis Chemotherapy. I. Single-dose Study. Am Rev Respir Dis. 1988;138(4):882-5. PubMed PMID: 3202464.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. I. Single-dose study. AU - Acocella,G, AU - Nonis,A, AU - Gialdroni-Grassi,G, AU - Grassi,C, PY - 1988/10/1/pubmed PY - 1988/10/1/medline PY - 1988/10/1/entrez SP - 882 EP - 5 JF - The American review of respiratory disease JO - Am. Rev. Respir. Dis. VL - 138 IS - 4 N2 - A comparative bioavailability study of the antituberculosis drugs isoniazid, rifampin, and pyrazinamide was carried out in a group of 10 healthy volunteers after administration of the three compounds, once in individual association and once in a combined, fixed preparation. The investigation was designed as an open, crossover study where each subject received five tablets of a preparation containing 50 mg isoniazid, 120 mg rifampin, and 300 mg pyrazinamide (corresponding to a total dose of 250 mg isoniazid, 600 mg rifampin, and 1,500 mg pyrazinamide). The same doses were administered in the session where the drugs were combined using the individual formulations. For each subject and experimental session, 15 blood samples were collected over a period of 24 h, and the plasma concentrations of the three drugs were assessed. The results indicated the absence of negative pharmacokinetic interactions between the drugs when administered in both free and this new, fixed combination. SN - 0003-0805 UR - https://www.unboundmedicine.com/medline/citation/3202464/Comparative_bioavailability_of_isoniazid_rifampin_and_pyrazinamide_administered_in_free_combination_and_in_a_fixed_triple_formulation_designed_for_daily_use_in_antituberculosis_chemotherapy__I__Single_dose_study_ L2 - http://www.atsjournals.org/doi/full/10.1164/ajrccm/138.4.882?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -